198 related articles for article (PubMed ID: 24332355)
1. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
[TBL] [Abstract][Full Text] [Related]
2. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
3. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Hofheinz RD; Lorenzen S; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Tetyusheva M; Heeger S; Vlassak S; Merx K
Ann Oncol; 2018 Apr; 29(4):1010-1015. PubMed ID: 29360920
[TBL] [Abstract][Full Text] [Related]
4. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
[TBL] [Abstract][Full Text] [Related]
5. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Schimanski CC; Staib F; Göhler T; Hebart H; Heike M; Neise M; Rudi J; Geer T; Dingeldein G; Lang C; Ehscheidt P; Flohr T; Josten KM; Karthaus M; Schmittel A; Wierecky J; Boller E; Indorf M; Wörns MA; Galle PR; Moehler M
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1023-1034. PubMed ID: 28197787
[TBL] [Abstract][Full Text] [Related]
6. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
7. Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
Gürbüz M; Akkuş E; Utkan G
J Oncol Pharm Pract; 2021 Mar; 27(2):480-484. PubMed ID: 32623964
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
9. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced skin toxicity and clinical nursing of VitK cream on colorectal cancer patients.
Li AM; Miao JH; Liu H; Ma YZ; Sun ZC
Pak J Pharm Sci; 2015 Jul; 28(4 Suppl):1499-503. PubMed ID: 26431649
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
[TBL] [Abstract][Full Text] [Related]
12. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Ann Oncol; 2018 Dec; 29(12):2393-2395. PubMed ID: 30307464
[No Abstract] [Full Text] [Related]
13. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
16. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
Rothschild SI; Betticher D; Zenhäusern R; Anchisi S; von Moos R; Pless M; Moosmann P; Popescu RA; Calderoni A; Dressler M; Rauch D; Pederiva S; Woelky R; Papet C; Bühler V; Borner M
Cancer Chemother Pharmacol; 2019 Oct; 84(4):881-889. PubMed ID: 31444619
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
19. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.
Wehler TC; Graf C; Möhler M; Herzog J; Berger MR; Gockel I; Lang H; Theobald M; Galle PR; Schimanski CC
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1667-72. PubMed ID: 23918349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
